One in five adults in the U.S. live with a mental illness and the COVID-19 pandemic has made the situation worse. The biotech industry is stepping in to address the issue, leading to the emergence of many mental health companies. There were at least 163 drugs targeting mental health under review or in the clinic according to a report last year from Pharmaceutical Research and Manufacturers of America. This article discusses eight such companies: Alto Neuroscience, atai Life Sciences, Axsome, Compass Pathways, Freedom Biosciences, MindMed, Relmada Therapeutics, and Vistagen.

Nearly 250,000 Records From Tax Credit Consulting Agency Exposed
Summarize this content to a maximum of 60 words: Research has uncovered an unencrypted, non-password-protected database containing 245,949 records.